|Bid||252.09 x 800|
|Ask||252.16 x 1100|
|Day's Range||250.71 - 254.15|
|52 Week Range||208.62 - 265.87|
|Beta (3Y Monthly)||1.23|
|PE Ratio (TTM)||75.21|
|Earnings Date||Aug 6, 2019|
|Forward Dividend & Yield||3.08 (1.21%)|
|1y Target Est||266.24|
In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.
FRANKLIN LAKES, N.J., July 18, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today provided an update on two voluntary recalls related to certain Alaris™ Pump Modules Model 8100 manufactured between April 2011 and June 2017 and certain model codes and lot numbers of the Alaris™ Pump Infusion Sets used with the Alaris™ Pump Model 8100. BD has already notified customers affected by these recalls. Both products were formerly marketed under the CareFusion brand, which BD acquired in March 2015.
The size of Becton, Dickinson and Company (NYSE:BDX), a US$68b large-cap, often attracts investors seeking a reliable...
FRANKLIN LAKES, N.J. , July 2, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2019 earnings conference ...
David King spent the bulk of his entire career turning around mutual funds, but now he runs a fund of his own design, the Columbia Flexible Capital Income fund.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Becton, Dickinson and Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Additionally, BD presented its own data confirming that the benefits outweigh the risks for LUTONIX® Drug-Coated Balloons (DCBs) in SFA. Over the past several months, BD has been working diligently to obtain all available patient follow up data and collaborating with FDA, professional clinical organizations and industry to investigate the important issue of DCB safety.
Becton Dickinson and Co NYSE:BDXView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for BDX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding BDX are favorable, with net inflows of $9.79 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. BDX credit default swap spreads are near the lowest level of the last three years and indicate the market's continued positive perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
Becton, Dickinson and Company (NYSE:BDX) saw significant share price movement during recent months on the NYSE, rising...
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FRANKLIN LAKES, N.J. , June 4, 2019 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the " Company " or " BD ") today announced the consideration payable in connection with ...
FRANKLIN LAKES, N.J., June 4, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today released a new report based on an independent national survey that examines drug diversion in U.S. hospitals, an underreported contributor to the opioid epidemic. Hospital drug diversion, when a health care worker "diverts" opiates or other controlled substances away from patients for personal use or sale, remains a significant challenge that is largely underdiscussed. Denial of the problem in their own hospitals – Executives and providers (nurses, pharmacists and anesthesiologists) may be in denial about the diversion problem in their own facilities.
FRANKLIN LAKES, N.J. , June 3, 2019 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the " Company " or " BD ") today announced the early tender results for its previously ...
FRANKLIN LAKES, N.J. , May 31, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Goldman Sachs ...
Dividend paying stocks like Becton, Dickinson and Company (NYSE:BDX) tend to be popular with investors, and for good...
Moody's Investors Service ("Moody's") today assigned Ba1 ratings to the senior unsecured notes to be offered by Becton Dickinson Euro Finance S.a.r.l. As part of the refinancing, BD plans to repay at maturity its euro 1 billion notes due in June 2019 and to tender for certain other outstanding notes of BD.
FRANKLIN LAKES, N.J., May 20, 2019 /PRNewswire/ -- Becton, Dickinson and Company (BDX) (the "Company" or "BD") today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, the "Securities" and each a "series"). The Company reserves the right, but is under no obligation, to increase any of the Tender SubCaps in the table above or the aggregate tender cap at any time, subject to applicable law.
Moody's Investors Service ("Moody's") today affirmed all of Becton, Dickinson & Company's ("BD") ratings including the Ba1 Corporate Family Rating, Ba1-PD Probability of Default Rating, Not Prime commercial paper rating, SGL-1 Speculative Grade Liquidity rating and the Ba1 senior unsecured rating. "The revision in the outlook to positive considers the deleveraging progress that BD has made since the closing of the Bard acquisition in December 2017" said Moody's Senior Vice President Scott Tuhy.